Bruker (NASDAQ:BRKR) VP Sells $98,400.00 in Stock

Bruker Corporation (NASDAQ:BRKR) VP Mark Munch sold 2,000 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total value of $98,400.00. Following the sale, the vice president directly owned 128,443 shares in the company, valued at $6,319,395.60. This trade represents a 1.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Mark Munch also recently made the following trade(s):

• On Monday, January 12th, Mark Munch sold 7,000 shares of Bruker stock. The stock was sold at an average price of $55.00, for a total value of $385,000.00.

Bruker Stock Down 2.2%

Shares of NASDAQ BRKR traded down $1.07 during mid-day trading on Friday, reaching $48.39. 2,332,889 shares of the company were exchanged, compared to its average volume of 2,863,517. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $61.01. The firm has a 50-day moving average of $47.02 and a 200 day moving average of $40.01. The stock has a market cap of $7.35 billion, a price-to-earnings ratio of -302.44, a P/E/G ratio of 6.34 and a beta of 1.17. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81.

Bruker (NASDAQ:BRKR) last announced its earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. During the same period in the previous year, the company posted $0.60 earnings per share. The firm’s revenue was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, research analysts expect that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Monday, December 8th were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date was Monday, December 8th. Bruker’s dividend payout ratio (DPR) is -125.00%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Wells Fargo & Company increased their price objective on Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Redburn Partners set a $60.00 target price on Bruker in a research report on Thursday, November 20th. UBS Group increased their price target on Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Citigroup boosted their price target on Bruker from $40.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $53.36.

Hedge Funds Weigh In On Bruker

Several hedge funds and other institutional investors have recently bought and sold shares of BRKR. Allworth Financial LP lifted its stake in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the period. Parallel Advisors LLC raised its holdings in shares of Bruker by 63.0% during the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after purchasing an additional 347 shares during the last quarter. UMB Bank n.a. lifted its position in Bruker by 26.3% during the second quarter. UMB Bank n.a. now owns 1,673 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 348 shares during the period. Linden Thomas Advisory Services LLC lifted its position in Bruker by 2.1% during the third quarter. Linden Thomas Advisory Services LLC now owns 19,669 shares of the medical research company’s stock valued at $639,000 after purchasing an additional 396 shares during the period. Finally, M&T Bank Corp boosted its holdings in Bruker by 2.7% in the second quarter. M&T Bank Corp now owns 15,580 shares of the medical research company’s stock valued at $642,000 after purchasing an additional 411 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.